Jeffrey Moffat is a Psychiatry physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
303 E Vanderbilt Way
San Bernardino, CA 924150026
Telephone
909-338-0890Provider last certified this registry record 28 Dec 2023.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Teva Pharmaceuticals USA, Inc.Program year20259 payments
- Neurocrine BioSciences, Inc.Program year20252 payments
- ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
88.5%Atypical Antipsychotic43.3%Clozapine30%Clozapine Odt15%Quetiapine Fumarate9%Olanzapine9%Invega Sustenna7%Vraylar6%Risperidone5%Abilify Maintena5%Lurasidone Hcl3%Ziprasidone Hcl3%Olanzapine Odt3%Zyprexa2%Asenapine Maleate1%Aripiprazole1%Secuado1%Perseris1%Quetiapine Fumarate Er1%Part D<11 patientsSSRI10.3%Sertraline Hcl31%Trazodone Hcl26%Fluoxetine Hcl12%Citalopram Hbr11%Escitalopram Oxalate7%Fluvoxamine Maleate6%Paroxetine Hcl6%Part D<11 patients+ 18 more classes in this area
Metabolism & gastrointestinal
4.1%Biguanide (metformin)2%Metformin Hcl Er70%Metformin Hcl30%Part D<11 patientsAnticholinergic1.7%Atropine Sulfate100%Part D<11 patients+ 1 more class in this area
Cardiovascular
4%Beta blocker4%Atenolol38%Propranolol Hcl Er31%Propranolol Hcl30%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2020–2022 per NIH RePORTER. The latest:
- Corticostriatal BDNF signaling in alcohol seeking and preference switching
University of California, San Francisco
FY2022$22,913F32AA028422 - Corticostriatal BDNF signaling in alcohol seeking and preference switching
University of California, San Francisco
FY2021$68,562F32AA028422 - Corticostriatal BDNF signaling in alcohol seeking and preference switching
University of California, San Francisco
FY2020$65,310F32AA028422
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”